Free Trial
→ Hedge fund legend humiliates Bitcoin traders (From Brownstone Research) (Ad)
NASDAQ:RENB

Renovaro 5/15/2024 Earnings Report

Renovaro logo
$0.34 0.00 (-0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 +0.01 (+2.23%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Renovaro EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Renovaro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Renovaro Announcement Details

Quarter
Date
5/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Renovaro Earnings Headlines

Renovaro subsidiary secures patent for drug discovery AI
June 6, 2025 | uk.investing.com
RENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingen
June 5, 2025 | nl.investing.com
Hedge fund legend humiliates Bitcoin traders
Larry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.
June 20, 2025 | Brownstone Research (Ad)
RENB stock touches 52-week low at $0.27 amid market challenges
June 5, 2025 | investing.com
Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics
June 5, 2025 | msn.com
Renovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkeling
June 3, 2025 | nl.investing.com
See More Renovaro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Renovaro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Renovaro and other key companies, straight to your email.

About Renovaro

Renovaro (NASDAQ:RENB), a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

View Renovaro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles